AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31194645 — intervention group
Group type: COMPARATOR
Intervention: Traditional three-level drug distribution system
Number of subjects: 439
Study 28645982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (nHF) therapy
Number of subjects: 0
Study 28645982 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 26553733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Mycobacterium w (Mw) vaccine
Number of subjects: 66
Study 26553733 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 66
Study 23904350 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition task with speeded responses to happy or sad faces
Number of subjects: 0
Study 23904350 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarity-based account
Number of subjects: 0
Study 23904350 — intervention group
Group type: COMPARATOR
Intervention: Conceptual-metaphor account
Number of subjects: 0
Study 22174039 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 195
Study 22174039 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 195
Study 19384242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroprusside
Number of subjects: 240
Study 19384242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 240
Study 19384242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 18416221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (autologous shed mediastinal blood)
Number of subjects: 90
Study 18416221 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (control group)
Number of subjects: 90
Study 15884752 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS‐75
Number of subjects: 144
Study 15884752 — intervention group
Group type: COMPARATOR
Intervention: ORS‐90
Number of subjects: 144
Study 12074773 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrostimulation (FES)
Number of subjects: 68
Study 12074773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract exercises (LUTE)
Number of subjects: 68
Study 12074773 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTE + FES
Number of subjects: 68
Study 12074773 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 68
Study 9719721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adduction group (20 patients)
Number of subjects: 40
Study 9719721 — intervention group
Group type: COMPARATOR
Intervention: Abduction group (20 patients)
Number of subjects: 40
Study 9350490 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical bipolar dissection technique (MBCT)
Number of subjects: 60
Study 9350490 — intervention group
Group type: COMPARATOR
Intervention: Cold sharp dissection with ligation for securing hemostasis (CSDL)
Number of subjects: 60
Study 9350490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study 1937659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise 3 times/wk (40 minutes at 60-70% maximum work capacity)
Number of subjects: 8
Study 7096587 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program lasting approximately 1 month designed to establish a systematic strategy of organizing complex visual material.
Number of subjects: 35
Study 7096587 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 patients) re-examined after 1 month without intervention.
Number of subjects: 35
Study 29948275 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme (FS) Ultra Universal
Number of subjects: 22
Study 29948275 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk (FB) Fill Flowable
Number of subjects: 22
Study 28415979 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)
Number of subjects: 59
Study 28415979 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SC)
Number of subjects: 59
Study 26476609 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 110
Study 26476609 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 110
Study 25038861 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI assessment using respiratory-triggered coronal EPI sequence (TR, 1400 ms; TE, 76 ms; diffusion direction, 6; NEX, 4; b values, 0 and 600 s/mm2; slices thickness, 6 mm)
Number of subjects: 75
Study 25038861 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 75
Study 23954520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate (IMMG)
Number of subjects: 30
Study 23954520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22152168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 0
Study 22152168 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (SH)
Number of subjects: 0
Study 19565120 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzyl benzoate (BB2 group) - two applications of 12.5% BB over 24 hours
Number of subjects: 181
Study 19565120 — intervention group
Group type: COMPARATOR
Intervention: Topical benzyl benzoate (BB1 group) - single application of 12.5% BB over 24 hours
Number of subjects: 181
Study 19565120 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin (IV group) - 150‐200 microg/kg
Number of subjects: 181
Study 17098762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 155
Study 17098762 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 155
Study 15293079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 25
Study 15293079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 25
Study 15293079 — intervention group
Group type: COMPARATOR
Intervention: Indinavir-containing HAART
Number of subjects: 25
Study 15293079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin and Fluvastatin
Number of subjects: 25
Study 11169174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed monochromatic infrared (956 nm) and red (637 nm) light therapy
Number of subjects: 0
Study 11169174 — intervention group
Group type: COMPARATOR
Intervention: Standard ulcer therapy (Control)
Number of subjects: 0
Study 10450730 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal Gastrectomy (SG)
Number of subjects: 618
Study 10450730 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 618
Study 7925339 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 gauge Yale needle
Number of subjects: 100
Study 7925339 — intervention group
Group type: COMPARATOR
Intervention: 24 gauge Sprotte needle
Number of subjects: 100
Study 2928151 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal temperature measurement
Number of subjects: 120
Study 2928151 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 120
Study 2928151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 120
Study 793705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) treatment, 20 mg/kg-d intravenously for 10 days after transplantation
Number of subjects: 179
Study 793705 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 179
Study 31489831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathering Through Change (FTC) intervention
Number of subjects: 426
Study 31489831 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 426
Study 28375641 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and Boswellia serrata supplement
Number of subjects: 16
Study 28375641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25935422 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5U alone (Placebo)
Number of subjects: 60
Study 25935422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5U + Calcium Chloride 200mg (CA-200)
Number of subjects: 60
Study 25935422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5U + Calcium Chloride 400mg (CA-400)
Number of subjects: 60
Study 23548916 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD II (MLC901)
Number of subjects: 0
Study 23548916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22149470 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 34
Study 22149470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19567110 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA strains isolated from wounds caused by earthquake (subtypes A, B, C, E)
Number of subjects: 11
Study 19567110 — intervention group
Group type: COMPARATOR
Intervention: MRSA strains isolated from non-earthquake-stricken areas (subtypes A, B, C, D)
Number of subjects: 11
Study 19567110 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MRSA strains from earthquake and non-earthquake areas
Number of subjects: 11
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin disorders prevalence
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigmentary disorders
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatitis/eczema and related conditions
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorders of skin appendages
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanocytic nevi (MN)
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐inflammatory pigmentation
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Scars
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acne
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dandruff
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediculosis capitis
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinflammatory hyper/hypo pigmentation
Number of subjects: 2239
Study 16501682 — intervention group
Group type: EXPERIMENTAL
Intervention: MN, dandruff, keratosis pilaris, acne, and folliculitis
Number of subjects: 2239
Study 12738463 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid sodium phosphate (45 ml at 7:00 PM, 45 ml 3 hours before colonoscopy)
Number of subjects: 101
Study 12738463 — intervention group
Group type: COMPARATOR
Intervention: Tablet sodium phosphate (20 tablets at 7:00 PM, 20 tablets 3-5 hours before colonoscopy)
Number of subjects: 101
Study 12738463 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid sodium phosphate
Number of subjects: 101
Study 12738463 — intervention group
Group type: COMPARATOR
Intervention: Tablet sodium phosphate
Number of subjects: 101
Study 11126465 — intervention group
Group type: EXPERIMENTAL
Intervention: YIPS
Number of subjects: 75
Study 11126465 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 9061218 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine eye drops administered 30 min after ASCC
Number of subjects: 20
Study 9061218 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine eye drops after 7 days of treatment, 30 min after ASCC
Number of subjects: 20
Study 9061218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8837422 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic infant milk formula (IMF) containing Bifidobacterium sp. strain LW420
Number of subjects: 17
Study 8837422 — intervention group
Group type: COMPARATOR
Intervention: Nonprobiotic infant milk formula (IMF)
Number of subjects: 17
Study 8837422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both probiotic and nonprobiotic IMF
Number of subjects: 17
Study 2674643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole with sunflower oil
Number of subjects: 86
Study 2674643 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole alone
Number of subjects: 86
Study 1102976 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet termination group
Number of subjects: 16
Study 1102976 — intervention group
Group type: COMPARATOR
Intervention: Diet continuation group
Number of subjects: 16
Study 1102976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 31595627 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help training (n = 130)
Number of subjects: 262
Study 31595627 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU; n = 132)
Number of subjects: 262
Study 30383540 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 238
Study 30383540 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17A response signature
Number of subjects: 238
Study 30383540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 28628488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, progressive strength and functional training intervention
Number of subjects: 110
Study 28628488 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity group training (Control)
Number of subjects: 110
Study 25846715 — intervention group
Group type: EXPERIMENTAL
Intervention: d-AMPH 5 mg/70 kg
Number of subjects: 37
Study 25846715 — intervention group
Group type: EXPERIMENTAL
Intervention: d-AMPH 10 mg/70 kg
Number of subjects: 37
Study 25846715 — intervention group
Group type: EXPERIMENTAL
Intervention: d-AMPH 20 mg/70 kg
Number of subjects: 37
Study 25846715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23999449 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 233
Study 23999449 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 233
Study 21224436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ω‐3 polyunsaturated fatty acids (PUFAs) administered as a single dose of a lipid emulsion containing 4.1 g of ω‐3 PUFAs during HD
Number of subjects: 44
Study 21224436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) administered during HD
Number of subjects: 44
Study 19922249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acem meditation (20 minutes)
Number of subjects: 0
Study 19922249 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest condition (20 minutes)
Number of subjects: 0
Study 16508584 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 8
Study 16508584 — intervention group
Group type: COMPARATOR
Intervention: Turner syndrome (TS)
Number of subjects: 8
Study 16508584 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 15195756 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl rest-redistribution SPECT
Number of subjects: 41
Study 15195756 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose SPECT
Number of subjects: 41
Study 10886487 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand beta2-agonist inhalation
Number of subjects: 80
Study 10886487 — intervention group
Group type: COMPARATOR
Intervention: Regular beta2-agonist inhalation
Number of subjects: 80
Study 9311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 0.5 mmol.l‐1 of Mg2+ (Group II)
Number of subjects: 38
Study 9311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 1.0 mmol.l‐1 of Mg2+ (Group III)
Number of subjects: 38
Study 9311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 2.0 mmol.l‐1 of Mg2+ (Group IV)
Number of subjects: 38
Study 9311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 4.0 mmol.l‐1 of Mg2+ (Group V)
Number of subjects: 38
Study 9311207 — intervention group
Group type: COMPARATOR
Intervention: Mg(2+)‐free acetated Ringer solution (Group I)
Number of subjects: 38
Study 8451670 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6
Study 8451670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-blockers)
Number of subjects: 6
Study 2951828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination fenoterol/ipratropium
Number of subjects: 20
Study 2951828 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study 30384941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) using hyrax appliances
Number of subjects: 30
Study 30384941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 30384941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 30
Study 26173589 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 55
Study 26173589 — intervention group
Group type: COMPARATOR
Intervention: Active control (isometric squats on a vibration platform without vibration)
Number of subjects: 55
Study 26173589 — intervention group
Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 55
Study 23356833 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A
Number of subjects: 112
Study 23356833 — intervention group
Group type: COMPARATOR
Intervention: Onabotulinum toxin A
Number of subjects: 112
Study 22401287 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-pulse TMS applied to the left FEF during the Simon task (0-40 msec and 40-80 msec after stimulus onset)
Number of subjects: 0
Study 22401287 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-pulse TMS applied to the right FEF during the Simon task (80-120 msec after stimulus onset)
Number of subjects: 0
Study 20386123 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass countermovement jumps (CMJs)
Number of subjects: 20
Study 20386123 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass CMJs
Number of subjects: 20
Study 18550933 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin receptor blocker)
Number of subjects: 809
Study 18550933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 15820793 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues and recombinant IL-2
Number of subjects: 24
Study 15820793 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogues without IL-2
Number of subjects: 24
Study 12439649 — intervention group
Group type: EXPERIMENTAL
Intervention: 2512 kJ (600 kcal) daily energy deficit diet (ED)
Number of subjects: 122
Study 12439649 — intervention group
Group type: EXPERIMENTAL
Intervention: 6279 kJ (1500 kcal) generalized low‐calorie diet (GLC)
Number of subjects: 122
Study 12439649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean red meat included in diet
Number of subjects: 122
Study 12439649 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance phase
Number of subjects: 122
Study 12439649 — intervention group
Group type: COMPARATOR
Intervention: Control period prior to dietary advice
Number of subjects: 122
Study 10338454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (>/=24‐hour insulin‐glucose infusion followed by multidose subcutaneous insulin)
Number of subjects: 620
Study 10338454 — intervention group
Group type: COMPARATOR
Intervention: Routine antidiabetic therapy (control group)
Number of subjects: 620
Study 10338454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 620
Study 10338454 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine antidiabetic therapy)
Number of subjects: 620
Study 8881840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 524
Study 8881840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 524
Study 1782080 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (two monthly cycles of intravenous doxorubicin/cyclophosphamide/5‐fluorouracil before locoregional therapy and four cycles subsequently)
Number of subjects: 196
Study 1782080 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (six monthly cycles following locoregional therapy)
Number of subjects: 196
Study 6184493 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 100
Study 6184493 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 100
Study 30526001 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ skills training (IST) only
Number of subjects: 281
Study 30526001 — intervention group
Group type: EXPERIMENTAL
Intervention: Program + IST
Number of subjects: 281
Study 30526001 — intervention group
Group type: COMPARATOR
Intervention: Program only
Number of subjects: 281
Study 30526001 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 281
Study 27817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (945 mg/day EPA + 510 mg/day DHA)
Number of subjects: 60
Study 27817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1000 mg/day EPA + 500 mg/day DHA)
Number of subjects: 60
Study 27817918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil 1500 mg/day)
Number of subjects: 60
Study 27817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 60
Study 27058408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung impedance (LI)‐guided treatment
Number of subjects: 256
Study 27058408 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment (Control)
Number of subjects: 256
Study 24494602 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 340
Study 24494602 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 340
Study 24494602 — intervention group
Group type: EXPERIMENTAL
Intervention: both AL and ASAQ
Number of subjects: 340